Brookstone Capital Management Invests $56,000 in Humacyte, Inc. (NASDAQ:HUMA)

Brookstone Capital Management acquired a new stake in Humacyte, Inc. (NASDAQ:HUMA) during the 4th quarter, HoldingsChannel.com reports. The fund acquired 11,105 shares of the company’s stock, valued at approximately $56,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. State Street Corp raised its holdings in shares of Humacyte by 66.1% during the third quarter. State Street Corp now owns 4,764,155 shares of the company’s stock valued at $25,917,000 after buying an additional 1,895,529 shares during the last quarter. Millennium Management LLC increased its position in Humacyte by 504.3% in the 2nd quarter. Millennium Management LLC now owns 1,599,307 shares of the company’s stock valued at $7,677,000 after acquiring an additional 1,334,641 shares during the period. Renaissance Technologies LLC raised its stake in Humacyte by 693.0% during the 2nd quarter. Renaissance Technologies LLC now owns 600,300 shares of the company’s stock valued at $2,881,000 after acquiring an additional 524,600 shares in the last quarter. Marshall Wace LLP boosted its position in Humacyte by 3,301.5% during the 2nd quarter. Marshall Wace LLP now owns 463,662 shares of the company’s stock worth $2,226,000 after acquiring an additional 450,031 shares during the period. Finally, Deerfield Management Company L.P. Series C bought a new position in shares of Humacyte in the second quarter worth $1,550,000. 44.71% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on HUMA shares. Benchmark lifted their price objective on shares of Humacyte from $15.00 to $17.00 and gave the company a “buy” rating in a research note on Monday, December 23rd. Piper Sandler set a $6.00 price target on shares of Humacyte and gave the stock a “neutral” rating in a research report on Friday, October 18th. HC Wainwright reiterated a “buy” rating and set a $15.00 price objective (up previously from $12.00) on shares of Humacyte in a research note on Friday, December 20th. BTIG Research restated a “buy” rating and issued a $10.00 target price on shares of Humacyte in a research report on Friday, October 18th. Finally, TD Cowen reiterated a “buy” rating and set a $10.00 price target on shares of Humacyte in a research report on Friday, October 18th. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $13.71.

Humacyte Stock Performance

Shares of NASDAQ:HUMA opened at $4.41 on Monday. The stock has a market capitalization of $555.04 million, a price-to-earnings ratio of -3.29 and a beta of 1.32. Humacyte, Inc. has a 1-year low of $2.53 and a 1-year high of $9.97. The company has a 50 day moving average price of $4.58 and a 200 day moving average price of $5.66.

Insider Transactions at Humacyte

In other Humacyte news, CEO Laura E. Niklason sold 811,172 shares of the company’s stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $4.44, for a total transaction of $3,601,603.68. Following the completion of the sale, the chief executive officer now directly owns 2,419,712 shares of the company’s stock, valued at approximately $10,743,521.28. This represents a 25.11 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Brady W. Dougan sold 427,459 shares of Humacyte stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $4.34, for a total transaction of $1,855,172.06. Following the completion of the transaction, the director now directly owns 1,992,253 shares in the company, valued at approximately $8,646,378.02. This trade represents a 17.67 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 1,500,000 shares of company stock valued at $6,606,799 in the last three months. 11.20% of the stock is currently owned by corporate insiders.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.